Filing Details

Accession Number:
0001209191-19-036426
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-12 17:00:25
Reporting Period:
2019-06-10
Accepted Time:
2019-06-12 17:00:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1370053 Anaptysbio Inc ANAB Pharmaceutical Preparations (2834) 203828755
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1654495 Hamza Suria C/o Anaptysbio, Inc.
10421 Pacific Center Court, Suite 200
San Diego CA 92121
President, Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-06-10 8,540 $72.64 31,524 No 4 S Direct
Common Stock Disposition 2019-06-10 6,440 $73.70 25,084 No 4 S Direct
Common Stock Disposition 2019-06-10 5,000 $74.68 20,084 No 4 S Direct
Common Stock Disposition 2019-06-10 1,994 $75.86 18,090 No 4 S Direct
Common Stock Disposition 2019-06-10 454 $76.31 17,636 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.16 to $73.15 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.20 to $74.15 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.20 to $75.12 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.24 to $76.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The Reporting Person also holds options to purchase up to an aggregate of 878,838 shares of common stock, which options vest according to their terms, in addition to the 17,636 shares of common stock held directly as set forth in Table I above.